Disease type and stage | Risk group |
Leukemia/MDS/MPN | CLL/SLL | CR or PR | Low |
Stable or progressive | Intermediate |
CML | Chronic phase | Low |
Accelerated phase | Intermediate |
Blast crisis | Very high |
AML | Favorable cytogenetics | CR | Low |
Induction failure or active relapse | High |
Intermediate cytogenetics | CR | Intermediate |
Induction failure or active relapse | High |
Adverse cytogenetics | CR | High |
Induction failure or active relapse | Very high |
ALL | First CR | Intermediate |
Second or third CR | High |
Induction failure or active relapse | Very high |
Low-risk MDS (<5 percent blasts) | Intermediate cytogenetics | Any stage | Intermediate |
Adverse cytogenetics | Early stage | Intermediate |
Induction failure or active relapse | High |
High-risk MDS (≥5 percent blasts) | Intermediate cytogenetics | Early stage | Intermediate |
Induction failure or active relapse | High |
Adverse cytogenetics | Any stage | High |
MPN | Any stage | Intermediate |
Lymphoma | Hodgkin lymphoma | CR | Low |
Mantle cell lymphoma | CR | Low |
PR | Intermediate |
Induction failure or active relapse | High |
Clinically indolent B cell NHL | CR or PR | Low |
Clinically aggressive B cell NHL | CR or PR | Intermediate |
Induction failure or active relapse | Very high |
Burkitt lymphoma | CR | High |
PR, induction failure, or active relapse | Very high |
T cell NHL | CR or PR | Intermediate |
Induction failure or active relapse | High |
Multiple myeloma | CR or PR | Intermediate |
Relapsed/refractory disease | High |
Risk group | Percentage of cases | Estimated two-year overall survival (95% CI) |
Low | 14 | 66 percent (63 to 68 percent) |
Intermediate | 63 | 51 percent (50 to 52 percent) |
High | 20 | 33 percent (31 to 35 percent) |
Very high | 4 | 23 percent (20 to 27 percent) |